Pregled po CROSBI profilu: Lucija Lešnjaković (CROSBI Profil: 38986, OBAD: -385708)

1.

Ganoci, L.; Lešnjaković, L.; Šimičević, L.; Palić, J.; Mucalo, I.; Božina, N.

DPYD haplotype structure for variants *2A, *13, c.2846A>T, c.1236G>A/HapB3, c.496A>G (rs2297595), *6 (rs1801160) and *9A (rs1801265) in the Croatian population // European Human Genetics Conference ; Hybrid Conference
Glasgow, Ujedinjeno Kraljevstvo, 2023. str. /-/ (poster, podatak o recenziji nije dostupan, sažetak, znanstveni)

2.

Lešnjaković, Lucija; Ganoci, Lana; Bilić, Ivan; Šimičević, Livija; Mucalo, Iva; Pleština, Stjepko; Božina, Nada

DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? // Pharmacogenomics, 24 (2023), 0135, 14 doi:10.2217/pgs-2022-0135 (međunarodna recenzija, pregledni rad, znanstveni)

doi www.futuremedicine.com

3.

Dominko, Kristina; Rastija, Ana; Smiljanić, Kosara; Mladenović, Aleksandra; Lešnjaković, Lucija; Kanazir, Selma; Milanović, Desanka; Hećimović, Silva

Pristup cjelovitom tekstu rada doi www.sciencedirect.com doi.org

4.

Božina, Nada; Bilić, Ivan; Ganoci, Lana; Šimičević, Livija; Pleština, Stjepko; Lešnjaković, Lucija; Trkulja, Vladimir

DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols // British journal of clinical pharmacology, 88 (2022), 5; 2190-2202 doi:10.1111/bcp.15144 (međunarodna recenzija, članak, znanstveni)

doi

5.

Ganoci, L.; Bilić, I.; Trkulja, V.; Lešnjaković, L.; Šimićević, L.; Mucalo, I.; pleština, S.; Božina, N.

DPYD polymorphism c.496A>G and risk of severe adverse drug reactions in cancer patients treated with fluoropyrimidine-based protocols // 8th European virtual congress of pharmacology (EPHAR 2021): From Great Science to better Medicine for Europe
online, 2021. str. /-/ (poster, međunarodna recenzija, sažetak, znanstveni)